US OptionsDetailed Quotes

MIRM241220C40000

Watchlist

4.00
0.000.00%

15min DelayClose Dec 3 16:00 ET

0.00High0.00Low

Mirum Pharmaceuticals Stock Discussion

TrendTrader

Jul 26 14:17

Looking for 45, 47 and 50

$Mirum Pharmaceuticals (MIRM.US)$

Mark Livermore

Jul 7 23:26

Watchlist

$Mirum Pharmaceuticals (MIRM.US)$
PROS-IPO on Jul 2019; triple digit on recent quarterly sales; ADR6.4%; dollar average volume>10MM; interesting volume; ATH; RS rating=89; near time high.
CONS-might need to wait for 10MA to catch up.
$iLearningEngines (AILE.US)$
PROS-IPO on Apr 2024 after business combination; AI theme; ADR12.33%; price increased approximately 90% in 1 month and sideway consolidate, building higher low and surphing 10 MA; vol drying up.
CONS-dollar volume between 1MM to 5...

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Meltyy

Mar 11 22:36

4 PDUFA decisions this week!

Last week’s PDUFAs:
$BeiGene (BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb (BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals (VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia (EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...

Meltyy

Feb 27 21:34

FDA Calendar-March

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia (EYEN.US)$ $Vanda Pharmaceuticals (VNDA.US)$ $Mirum Pharmaceuticals (MIRM.US)$ $Madrigal Pharmaceuticals (MDGL.US)$ $Geron (GERN.US)$ $Bristol-Myers Squibb (BMY.US)$ $2seventy bio (TSVT.US)$ $Legend Biotech (LEGN.US)$ $OptiNose (OPTN.US)$ $Orchard Therapeutics (ORTX.US)$ $Merck & Co (MRK.US)$ $Akebia Therapeutics (AKBA.US)$ $AstraZeneca (AZN.US)$ $Liquidia (LQDA.US)$ $Esperion Therapeutics (ESPR.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $BeiGene (BGNE.US)$

Mcsnacks H Tupack

Feb 23 05:45

March 13-16 FDA Upcoming reviews

A huge 3 day span will see 7 companies in front of the review board:
$Mirum Pharmaceuticals (MIRM.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Geron (GERN.US)$
$Bristol-Myers Squibb (BMY.US)$
$Legend Biotech (LEGN.US)$
$2seventy bio (TSVT.US)$
$OptiNose (OPTN.US)$

Moomoo AI

Dec 26, 2023 09:32

Multiple insider sales at Mirum Pharmaceuticals raises potential investor concern, despite insider purchase by CFO displaying some confidence in the firm's future. Notably, insider ownership indicates alignment between management and smaller shareholders.

Multiple Insiders Sold Mirum Pharmaceuticals Shares Presenting Weak Signs For Investors

Explore moomoo's "Insider Activity" for institutional sentiment

Moomoo AI

Oct 17, 2023 08:11

Mirum Pharmaceuticals' muted future revenue growth compared to broader industry may struggle to support its current P/S ratio. The modest growth could potentially drag down shares despite maintaining current prices.

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business Is Yet to Catch Up With Its Share Price

BioPharm Insight US

Nov 7, 2022 10:19

Columns Weekly FDA Drug Pipeline Calendar (Nov 7 - Nov 11)

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
Lab-grown blood given to humans in world-first trial aimed at combatting rare disorders
Blood grown in a laboratory has been transfused into humans for the first time in a landmark clinical trial that U.K. researchers say could significantly improve treatment for people with blood disorders and r...

Cramer ETF

Aug 31, 2022 00:53

'It Is Too Sizzling For Me': Why Jim Cramer Isn't Buying This 'Red Hot' Group Of Stocks.

$Kelly Services-A (KELYA.US)$ $PepsiCo (PEP.US)$ $Mirum Pharmaceuticals (MIRM.US)$ On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them. That’s why that stock has been such a dog. You never know, but I am not a buyer of it right here, though."
When asked about PepsiCo, Inc. , Cram...

No comment yet